ZYME
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Tuesday, November 18, 2025 BiopharmaWatch Research 1 min read Key Takeaway: Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Price reaction · baseline $23.9 (2025-11-17 close) · hit after-hours · clean, no other ZYME news in the window
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+23%
120-day peak, hindsight
Typical move
5.4%
average across 7 past catalysts
Cash runway
~35 mo
Minimal dilution risk
Lead asset
ZW49
Phase 1 · HER2-expressing Cancers
Full Press Release Details
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer.